Cargando…

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder closely linked with type II diabetes (T2D). The progression of NAFLD is associated with the induction of lipogenesis through hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. An increase in lipogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yu Seol, Park, Jeong Su, Lee, Da Hyun, Lee, Dong-Kyu, Kwon, Sung Won, Lee, Byung-Wan, Bae, Soo Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161559/ https://www.ncbi.nlm.nih.gov/pubmed/30298052 http://dx.doi.org/10.3389/fendo.2018.00539

Ejemplares similares

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Mechanistic Target of Rapamycin Pathway in Epileptic Disorders
por: Kim, Jang Keun, et al.
Publicado: (2019)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
por: Shin, Na-Rae, et al.
Publicado: (2018)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
por: Lee, Yong-ho, et al.
Publicado: (2017)

N-Acetylaspartate Metabolism Outside the Brain: Lipogenesis, Histone Acetylation, and Cancer
por: Bogner-Strauss, Juliane G.
Publicado: (2017)

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Positioning-dependent bidirectional NELL2 signaling in the brain
por: Lee, Byung Ju, et al.
Publicado: (2022)

Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
por: Lee, Da Young, et al.
Publicado: (2017)

Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes
por: Yim, Jisook, et al.
Publicado: (2018)

Antidiabetic and Beta Cell-Protection Activities of Purple Corn Anthocyanins
por: Hong, Su Hee, et al.
Publicado: (2013)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Microbiota: A potential orchestrator of antidiabetic therapy
por: Liu, Bingyao, et al.
Publicado: (2023)

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
por: Ryang, Soree, et al.
Publicado: (2022)

FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
por: Szczepańska, Ewa, et al.
Publicado: (2022)

Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis
por: Choi, Young Sik, et al.
Publicado: (2018)

OR17-01 Leptin Decreases De Novo Lipogenesis in Lipodystrophic Patients
por: Baykal, Annah Petek, et al.
Publicado: (2020)

Intrauterine food restriction impairs the lipogenesis process in the mesenteric adipocytes from low-birth-weight rats into adulthood
por: Andreotti, Sandra, et al.
Publicado: (2023)

Polycystin-2 Is Required for Starvation- and Rapamycin-Induced Atrophy in Myotubes
por: Kretschmar, Catalina, et al.
Publicado: (2019)

Proximity-Directed Labeling Reveals a New Rapamycin-Induced Heterodimer of FKBP25 and FRB in Live Cells
por: Lee, Song-Yi, et al.
Publicado: (2016)

Mammalian Target of Rapamycin Complex 1 Suppresses Lipolysis, Stimulates Lipogenesis, and Promotes Fat Storage
por: Chakrabarti, Partha, et al.
Publicado: (2010)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Inherited Disorders of Thyroid Hormone Metabolism Defect Caused by the Dysregulation of Selenoprotein Expression
por: Lee, Kyu Won, et al.
Publicado: (2022)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Predictive Factors of Conception and the Cumulative Pregnancy Rate in Subfertile Couples Undergoing Timed Intercourse With Ultrasound
por: Ahn, So Hyun, et al.
Publicado: (2021)

Palmitoleic Acid Decreases Non-alcoholic Hepatic Steatosis and Increases Lipogenesis and Fatty Acid Oxidation in Adipose Tissue From Obese Mice
por: Cruz, Maysa M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oblmdt6jmr2apmncdqmk36h974